Devyser Diagnostics (OM:DVYSR) remains unprofitable, with losses having grown 16.9% per year over the past five years. However, the company is forecast to become profitable within the next three years ...

Devyser Diagnostics AB (OSTO:DVYSR) is set to release its Q1 2025 earnings on Apr 29, 2025. The consensus estimate for Q1 2025 revenue is $57.18 million, and the earnings are expected to come in at ...

In light of this morning's communication that Fredrik Alpsten is leaving his position as CEO of Devyser and to avoid speculation, Devyser is releasing a summary of the year-end report for 2024 before ...

Welcome to Devyser Diagnostics Q1 Report 2026 presentation. [Operator Instructions] Now I will hand the conference over to the speakers. CEO, Jan Wahlstrom; and CFO, Sabina Berlin. Please go ahead.

Devyser launches first IVDR-certified productIn March, Devyser launched Compact, the company's first IVDR-certified product. This is a rapid genetic test for the diagnosis of fetal chromosomal ...

Welcome to Devyser Diagnostics Q4 Report 2025 Presentation. [Operator Instructions] Now I will hand the conference over to the speakers, CEO, Jan Wahlstrom; CFO, Sabina Berlin; and CCO, Theis Kipling.